Clay Siegall Ph.D. is the founder and CEO of the drug firm Seattle Genetics. He helps create targeted cancer drugs that he predict will help bring about a change in the way patients treat themselves. With the release of the first FDA approved conjugate on the market they prove they are well on their way.
Dr. Siegall predicts that chemotherapy drugs are on their way out. Hopes are high that the old way to treat cancer, which is brutal and unforgiving, is about to change for the better. With new drugs like the one his company released, called ADCETRIS, there is new hope daily.
The company, Seattle Genetics, was founded in 1998. They have since developed the first FDA approved conjugate on the market. There are multiple approved applications for the new treatments. There are over another 20 drugs in the pipeline at Seattle Genetics. They have also partnered with companies such as Bayer, Pfizer, and Genentech.
Theere is a high risk associated with the pharmaceutical companies. Only about one out of every ten medications makes it through the stringent FDA regulations.
When asked about the success of his company Dr. Siegall said that to achieve success, one of his favorite tips to give people is collaboration. He states that to collaborate with others expands the possibilities for one’s own business, as well as being able to share ideas and resources.
Dr. Clay Siegall started in this industry as a result of seeing a family member get sick. When his family member almost died from anemia as a result of chemotherapy, he decided that there had to be a better way. This led him to study genetics and start Seattle Genetics so that he could continue searching for better treatments.
Dr. Siegall has his B.S. in Zoology from University of Maryland. He went on and earned his Ph.D. in genetics at George Washington University.